These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21044870)

  • 1. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
    Hjorth M; Axelsson S; Rydén A; Faresjö M; Ludvigsson J; Casas R
    Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.
    Pihl M; Akerman L; Axelsson S; Chéramy M; Hjorth M; Mallone R; Ludvigsson J; Casas R
    Clin Exp Immunol; 2013 Jun; 172(3):394-402. PubMed ID: 23600827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
    Axelsson S; Hjorth M; Akerman L; Ludvigsson J; Casas R
    Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes.
    Boettler T; Pagni PP; Jaffe R; Cheng Y; Zerhouni P; von Herrath M
    J Autoimmun; 2013 Aug; 44():40-8. PubMed ID: 23770292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insufficient increment of CD4+CD25+ regulatory T cells after stimulation in vitro with allergen in allergic asthma.
    Wang LH; Lin YH; Yang J; Guo W
    Int Arch Allergy Immunol; 2009; 148(3):199-210. PubMed ID: 18849611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients.
    Pihl M; Barcenilla H; Axelsson S; Chéramy M; Åkerman L; Johansson I; Ludvigsson J; Casas R
    Clin Immunol; 2017 Mar; 176():114-121. PubMed ID: 28131926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells.
    Aarts-Riemens T; Emmelot ME; Verdonck LF; Mutis T
    Eur J Immunol; 2008 May; 38(5):1381-90. PubMed ID: 18412171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC.
    Li L; Chao QG; Ping LZ; Xue C; Xia ZY; Qian D; Shi-ang H
    Cancer Biother Radiopharm; 2009 Jun; 24(3):357-67. PubMed ID: 19538059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.
    Arif S; Gomez-Tourino I; Kamra Y; Pujol-Autonell I; Hanton E; Tree T; Melandri D; Hull C; Wherrett DK; Beam C; Roep BO; Lorenc A; Peakman M
    Diabetologia; 2020 Jun; 63(6):1186-1198. PubMed ID: 32248243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
    Axelsson S; Chéramy M; Hjorth M; Pihl M; Akerman L; Martinuzzi E; Mallone R; Ludvigsson J; Casas R
    PLoS One; 2011; 6(12):e29008. PubMed ID: 22174945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.
    Axelsson S; Hjorth M; Ludvigsson J; Casas R
    Diabet Med; 2012 Oct; 29(10):1272-8. PubMed ID: 22587593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GAD-alum immunotherapy in Type 1 diabetes mellitus.
    Morales AE; Thrailkill KM
    Immunotherapy; 2011 Mar; 3(3):323-32. PubMed ID: 21395375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
    Chéramy M; Skoglund C; Johansson I; Ludvigsson J; Hampe CS; Casas R
    Clin Immunol; 2010 Oct; 137(1):31-40. PubMed ID: 20580618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes.
    Ryden A; Stechova K; Durilova M; Faresjö M
    Diabetes Metab Res Rev; 2009 May; 25(4):335-43. PubMed ID: 19382103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
    Tavira B; Barcenilla H; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
    J Diabetes Res; 2018; 2018():9391845. PubMed ID: 30009185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice.
    Pop SM; Wong CP; He Q; Wang Y; Wallet MA; Goudy KS; Tisch R
    Diabetes; 2007 May; 56(5):1395-402. PubMed ID: 17317763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
    Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
    J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
    Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
    N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
    Axelsson S; Chéramy M; Akerman L; Pihl M; Ludvigsson J; Casas R
    Diabetes Care; 2013 Nov; 36(11):3418-24. PubMed ID: 23863909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher FoxP3 mRNA expression in peripheral blood mononuclear cells of GAD65 or IA-2 autoantibody-positive compared with autoantibody-negative persons.
    Link M; Salur L; Kisand K; Rajasalu T; Tillmann V; Uibo R
    APMIS; 2008 Oct; 116(10):896-902. PubMed ID: 19132983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.